EcoDrugPlus

Sodium Channel, Voltage-Gated, Type Iv, Alpha

Ensembl ID : ENSPEMG00000013778
Gene Symbol: SCN4A
1 Cross references
193 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type V, Alpha

Ensembl ID : ENSPEMG00000020279
Gene Symbol: SCN5A
1 Cross references
94 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type Viii, Alpha

Ensembl ID : ENSPEMG00000014356
Gene Symbol: SCN8A
1 Cross references
274 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSPEMG00000020122
Gene Symbol: SCN10A
3 Cross references
297 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 11

Ensembl ID : ENSPEMG00000018380
Gene Symbol: SCN11A
3 Cross references
96 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSPEMG00000019127
Gene Symbol: SCN7A
3 Cross references
86 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSPEMG00000010302
Gene Symbol: SCN9A
3 Cross references
110 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-4

Ensembl ID : ENSPEMG00000000606
Gene Symbol: LOC102905089
3 Cross references
564 Possible Orthologues:

Solute Carrier Family 10, Member 2

Ensembl ID : ENSPEMG00000015438
Gene Symbol: SLC10A2
1 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSPEMG00000008504
Gene Symbol: SLC18A2
3 Cross references
223 Possible Orthologues:

Solute Carrier Family 22 (Organic Anion Transporter), Member 6

Ensembl ID : ENSPEMG00000010064
Gene Symbol: SLC22A6
1 Cross references
490 Possible Orthologues:

Solute Carrier Family 22 (Organic Anion Transporter), Member 8

Ensembl ID : ENSPEMG00000005685
Gene Symbol: SLC22A8
1 Cross references
310 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).